Benjamin Buck

Dr. Benjamin Buck


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2017 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
PDF file
Avirup GuhaAvirup Guha
Avirup Guha
XXXiao Xiang
Xiao Xiang
DHDevin Haddad
Devin Haddad
BBBenjamin Buck
Benjamin Buck
XGXu Gao
Xu Gao
EDEmile G. Daoud
Emile G. Daoud
Background: Pacemakers (PM) are used for managing sick sinus syndrome (SSS). This study evaluates predictors and trends of PM implantation for SSS.Methods: Patients were identified from the National Inpatient Sample dataset (2003–2013). Included patients were ≥18 years old, had a diagnosis of sinus node dysfunction and atrial arrhythmia (i.e., SSS). Patients who died, transferred out, who had prior device, or had a defibrillator or resynchronization therapy device implanted were excluded. Included patients were then stratified by if a PM was implanted. Data regarding SSS, trends of PM utilization, and multivariable models of factors associated with PM implantation are presented.Results: Note that 328,670 patients satisfied study criteria. This study compared patients who underwent (87.4%) PM implantation to those who did not undergo (12.6%) PM implantation. The annual trends for hospitalization with SSS and PM placement have been decreasing (P <0.001). Variables associated with lower likelihood for PM implantation include young age, female sex, non‐Caucasian race, chronic heart failure, Charlson Comorbidity Score ≥1, emergency room and weekend admission, hospital stay ≤3 days, and high cardiology inpatient volume. Greater likelihood for PM implantation was associated with hyperlipidemia, hypertension, and hospitals that were either private, large, Northeastern location, or with high cardiac procedural volume.Conclusions: Analyzing 11‐year data from a national inpatient database demonstrate a number of relevant variables that impact PM utilization that include not only clinical but also nonclinical variables such as socioeconomic status, gender, and hospital features. Racial and gender bias toward PM implantation are unchanged and persist through 2013.

1 March 2018 in Indian Pacing and Electrophysiology Journal
Verified
Journal Article
Open access
XGXu Gao
Xu Gao
Avirup GuhaAvirup Guha
Avirup Guha
BBBenjamin Buck
Benjamin Buck
DPDilesh Patel
Dilesh Patel
MSMelissa J. Snider
Melissa J. Snider
EDEmile G. Daoud
Emile G. Daoud
Expert opinion recommends performing exercise testing with initiation of Class Ic antiarrhythmic medication. To evaluate the rate and reason for discontinuation of Ic agent within the first year of follow up, with particular attention to rate of proarrhythmia and the value of routine treadmill testing. This is a single center retrospective cohort study including consecutive patients with atrial arrhythmias who were initiated on a Class Ic agent from 2011 to 2016. Data was collated from chart review and pharmacy database. The study population included 300 patients (55% male, mean age 61; mean ejection fraction, 56%) started on flecainide (n = 153; 51%) and propafenone (n = 147; 49%). Drug initiation was completed while hospitalized on telemetry and the staff electrophysiologists directed dosing. There was one proarrhythmic event during initiation (0.3%). The primary reason for not being discharged on Ic agent was due to detection of proarrhythmia (n = 15) or ischemia (n = 1) with treadmill testing (5.3%). Exercise testing was the single significant variable to affect the decision to discontinue Ic drug, p < 0.0001 (95% CI: 1.89-6.08%). During follow up, the primary reason for discontinuation of Ic agent was lack of efficacy, 32%. With proper screening, initiation of Class Ic agent is associated with very low rate of proarrhythmia. Treadmill testing is of incremental value and should be completed in all patients after loading Class Ic antiarrhythmic.

10 September 2019 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
ABAlex Baher
Alex Baher
BBBenjamin Buck
Benjamin Buck
MFManuel Fanarjian
Manuel Fanarjian
JMJ. Paul Mounsey
J. Paul Mounsey
AGAnil Gehi
Anil Gehi
JHJames P. Hummel
James P. Hummel

7 November 2025 in Circulation Research
Verified
Journal Article
Closed access
DNDrew M. Nassal
Drew M. Nassal
SMShivangi Mohta
Shivangi Mohta
RSRebecca Shaheen
Rebecca Shaheen
HLHaiyan Liu
Haiyan Liu
OCOmer Cavus
Omer Cavus
Thomas J. HundThomas J. Hund
Thomas J. Hund
BACKGROUND: Cardiac hypertrophy, defined as a stress-induced increase in heart mass/size, is a major risk factor for adverse cardiovascular events, including heart failure and arrhythmia. Within this general definition, the orientation of cell and organ growth varies considerably depending on stress type and duration, with important implications for cardiac function, yet little is known regarding the mechanisms that regulate hypertrophic orientation. Here, we evaluated the role of the cytoskeletal protein β IV -spectrin and associated prohypertrophic STAT3 (signal transducer and activator of transcription 3) to direct the orientation of hypertrophic growth. METHODS: Transgenic mouse models with altered STAT3 signaling through modified interaction with its scaffolding partner β IV -spectrin, or phospho-regulation of STAT3 directly, were evaluated at baseline, and after transaortic constriction, or aortocaval fistula. Unbiased screening of gene expression from these structurally divergent states was evaluated for pathways responsible for directing myocyte length/width. These pathways were tested in vitro using primary mouse myocytes and in vivo to tune growth patterns for therapeutic intervention. RESULTS: Loss of β IV -spectrin or direct STAT3 activation promoted a preferential increase in myocyte length over width, resulting in dilation of the left ventricular chamber (eccentric hypertrophy) and decreased systolic function. Conversely, preservation of β IV -spectrin favored an increase in myocyte width without left ventricular dilation (concentric hypertrophy) and preserved systolic function in response to transaortic constriction or aortocaval fistula. Differential expression of genes associated with microtubules, including the trafficking kinesin motor, KIF20A (kinesin family member 20A), were identified in concentric versus eccentric hypertrophic states. In vitro assays revealed a relationship between β IV -spectrin/STAT3 signaling, KIF20A expression, microtubule density, and spatial distribution of mRNA for the sarcomeric gene actc1 . Finally, intervention with pharmacological STAT3 inhibition after chronic 6-week transaortic constriction successfully recovered concentric growth with improved systolic function. CONCLUSIONS: These data identify a novel and pivotal role for β IV -spectrin/STAT3 to modify microtubule properties and sarcomeric transcript distribution to direct myocyte geometry in response to chronic stress. These studies further illustrate the unique separation of hypertrophic growth and orientation as distinct pathways in cardiac remodeling.

1 July 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
CJCemantha M. L. Johnson
Cemantha M. L. Johnson
DNDrew M. Nassal
Drew M. Nassal
AWAlexander J. Winkle
Alexander J. Winkle
BBBenjamin Buck
Benjamin Buck
XXXianyao Xu
Xianyao Xu
Thomas J. HundThomas J. Hund
Thomas J. Hund
A major finding of this study is the involvement of the background K+ channel TREK-1 in modulating STAT3 activation, profibrotic gene expression, and fibrosis with implications for the cardiac remodeling response to chronic pressure overload.

22 July 2019 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
BBBenjamin Buck
Benjamin Buck
TOToshimasa Okabe
Toshimasa Okabe
Avirup GuhaAvirup Guha
Avirup Guha
EDEmile Daoud
Emile Daoud